**Handbook of dermatologic drug therapy**

**Draft Table of Contents**

**Section I: Introduction History of dermatologic therapy relevant to India**

**Section II: Basic principles of pharmacology including** Pharmacodynamics and Pharmacokinetics, Polymorphisms, Stability of Dermatologic Drugs, Pharmacovigilance: Safety of dermatologic drugs, Phases of Drug Approval

**Section III: Topical drugs used in Dermatology**

Chapter 1. Principles of topical therapy, formulations, drug delivery systems

Chapter 2. Antibacterial Agents

Chapter 3. Antifungal agents

Chapter 4. Antiviral agents

Chapter 5. Antiparasitic agents

Chapter 6. Corticosteroids

Chapter 7. Retinoids

Chapter 8. Chemotherapeutic/antimitotic agents

Chapter 9. Immunomodulators (including Irritants/Counter-irritants, Topical calcineurin inhibitors, Topical Vitamin D3 analogues, etc.)

Chapter 10. Antipruritics

Chapter 11. Demelanizing agents

Chapter 12. Keratolytic agents

Chapter 13. Moisturizers

Chapter 14. Miscellaneous topical drugs (Sunscreens, Therapeutic shampoos, α-Hydroxy acids, Products for the care of chronic wounds, Ascorbic acid, anti-oxidants, anti-perspirants, minoxidil, anthralin, timolol, bimatoprost, aloe vera)

**Section IV: Systemic drugs used in dermatologic treatment**

Chapter 1. Antibacterial Agents

 Chapter 2. Antifungal agents

 Chapter 3. Antiviral agents

 Chapter 4. Antiretroviral agents

 Chapter 5. Antiparasitic agents

 Chapter 6. Antileprosy drugs

 Chapter 7. Antituberculosis drugs

 Chapter 8. Systemic corticosteroids

 Chapter 9. Antihistamines and Mast cell stabilizers

 Chapter 10. Cytotoxic agents (Azathioprine, Methotrexate, Mycophenolate mofetil and mycophenolic acid, Cyclosporine, etc)

 Chapter 11. Antimalarial agents

 Chapter 12. Systemic retinoids

 Chapter 13. Photochemotherapy and other phototherapy modalities

 Chapter 14. Systemic Photoprotective agents

 Chapter 15. Anti-androgens / androgen inhibitors,

 Chapter 16. Miscellaneous systemic drugs (including Vasoactive and antiplatelet agents, Antiandrogens and androgen inhibitors, Psychotropic agents, drying agents, Potassium Iodide, Colchicine, PDE4 inhibitors, Danazol, Non-steroidal anti-inflammatory drugs, Vitamins & minerals, Leflunomide, Tranexamic acid)

 Chapter 17. Infusions or injectables (intravenous/ subcutaneous /intramuscular) including Biologicals & Immunobiologicals, Plasmapheresis, Corticosteroids, Anti-mitotics)

**Section V**

Chapter 1. Intralesional drugs used in Dermatology including Corticosteroids, Antiviral agents, Immunotherapy, Chemotherapeutic agents

Chapter 2. Mesotherapy & Microneedling,

Chapter 3. Local anesthetics in dermatology

Chapter 4. Sclerosants

**Section VI: Cosmeceuticals & Drugs used in Cosmetology**

Chapter 1. Cosmeceuticals

Skin- Creams, cleansers, disinfectants, deodorants

Hair- Shampoos, conditioners, hair dyes

Nail Cosmetics

Cosmetic Camouflage

Chapter 2. Chemical peels

Chapter 3. Tattooing

Chapter 4. Dermal and subcutaneous fillers

Chapter 5. Botulinum toxin

**Section VII: Vaccines in Dermatology**

**Section VIII: Drug therapy in special situations**

Chapter 1. Pregnancy & Lactation

Chapter 2. Children

Chapter 3. Geriatric population

Chapter 4. Liver disease

Chapter 5. Kidney disease

Chapter 6. Cardiac disease

Chapter 7. Immunocompromised patients

**Section IX: Adverse effects of dermatologic drug therapy**

Chapter 1. Cutaneous adverse effects

Chapter 2. Mucosal adverse effects

Chapter 3. Systemic adverse effects

Chapter 4. Hepatic toxicity

Chapter 5. Hematologic toxicity

Chapter 6. Renal toxicity

Chapter 7. Neurologic and psychiatric adverse effects

Chapter 8. Carcinogenicity

Chapter 9. Drug interactions

Chapter 10. Clinico-pathological spectrum of various drug reactions

**Section X: Practical issues in therapeutics**

Chapter 1. Ethical prescribing and medicolegal issues in drug reactions

Chapter 2. Drug dispensing in dermatology

Chapter 3. Drug de-sensitization

Chapter 4. Managing adverse effects of ATT

**Section XI: Recent Advances**

Chapter 1. Recent advancesincluding Statins, JAK-STAT inhibitors, Interleukin inhibitors

Chapter 2. Nasal route drug delivery and other topical delivery systems

Chapter 3. Nanotechnology in dermatology

**Section XII: Traditional drug therapy for common dermatoses**

**Section XIII: Pharmacoeconomics**

**Section XIV: Pharmacogenomics**

**Section XV Appendix**

Appendix I. Consent form

Appendix II. Adverse drug reaction reporting form

Appendix III. Patient education and informed consent documents for dapsone, isotretinoin, thalidomide and immunosuppressants

Appendix IV. ITATSA – An IADVL endeavor to prevent steroid abuse